Response of HCV Yemeni Patients to Sofosbuvir/Ledipasvir in Combination with Ribavirin - Open Access Library Journal

OALibJ > Vol.6 No.6, June 2019

Response of HCV Yemeni Patients to Sofosbuvir/Ledipasvir in Combination with Ribavirin ()

Download as PDF (Size: 212KB) PP. 1-9

DOI: 10.4236/oalib.1105507 87 Downloads 648 Views

Author(s)

Abdulgafoor Kassim¹, Ramea Alathwary^2*, Talal Al-hogami³

Affiliation(s)

¹Gastroenterology and Hepatology, Internal Medicine, Faculty of Medicine, Taiz University, Taiz, Yemen.
²Internal Medicine, Internal Medicine Department, Faculty of Medicine, Taiz University, Taiz, Yemen.
³Alfa Medical Lab, Ibb, Yemen.

ABSTRACT

Objectives: To study the effectiveness and safety of ledipasvir-sofosbuvir plus ribavirin treatment in Yemeni patient with HCV infection. Design: Prospective study of sixty-five Yemeni patients confirmed with HCV infection during the period from January 2017 to April 2018. Setting: Gastrointestinal and liver diseases specialized center in Ibb city, Yemen. Subjects: Patients with proved HCV infection by PCR. Results: We collected 65 cases with HCV infection. They were 19 (29.2%) males and 46 (70.8) females with age ranged between 18 years and 70 years and the mean age was 47.98 ± 11.90 years. sixteen (24.6%) of them had compensated liver cirrhosis and the remainder were non-cirrhotic healthy individual. The early virological response reported in 100% of cases while the sustained virological response (SVR) reported in 90.8%. The reported side effects of our patients were fatigue in (24.6%), abdominal pain in (13.8%), diarrhea in (10.8%), insomnia in (9.2%), headache in (7.7%), and nausea/vomiting in (7.7%). Conclusion: The Sofosbuvir-ledipasvir plus Ribavirin treatment was highly effective and safe for the treatment of hepatitis C patients in Yemen.

KEYWORDS

HCV, Early Virological Response (EVR), MPIVIROPACT Plus, Yemen

Share and Cite:

Kassim, A. , Alathwary, R. and Al-hogami, T. (2019) Response of HCV Yemeni Patients to Sofosbuvir/Ledipasvir in Combination with Ribavirin. Open Access Library Journal, 6, 1-9. doi: 10.4236/oalib.1105507.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies